Managed care and the impact of glaucoma

American Journal of Managed Care

Volumn 14, Issue SUPPL. 1, 2008, Pages

  Reeder, Claiborne E ^a   Franklin, Meg ^b   Bramley, Thomas J ^b  

^a XCENDA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; TIMOLOL;

DRUG COST; FOLLOW UP; GLAUCOMA; HEALTH CARE SYSTEM; HUMAN; INTRAOCULAR PRESSURE; MANAGED CARE ORGANIZATION; MEDICAL CARE; NEUROPROTECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; TRABECULOPLASTY;

AGED; GLAUCOMA; HEALTH CARE COSTS; HUMANS; MANAGED CARE PROGRAMS; MASS SCREENING; MIDDLE AGED; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 40349108274     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol. 1991;134:1102-1110.
2. Weston BC, Aliabadi Z, White GL. Glaucoma - review for the vigilant clinician. Clin Rev. 2000;10:59-74.
3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
4. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122:532-538.
5. Distelhorst JS, Hughes GM. Open-angle glaucoma. Am Fam Physician. 2003;67:1937-1944.
6. Kass MA, Heur DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
7. Riordan-Eva P, Vaughan DG. Eye. In: Tierney LM Jr, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis & Treatment. 40th ed. New York, NY: Lange Medical Books/McGraw-Hill; 2001:185-216.
8. American Academy of Ophthalmology. Primary open angle glaucoma, preferred practice patterns. San Francisco: American Academy of Ophthalmology, 2005. www.aao.org/ppp. Accessed February 15, 2007.
9. Javitt JC, Zhou Z, Wilke RJ. Association between vision loss and higher medical care costs in Medicare beneficiaries: costs are greater for those with progressive vision loss. Ophthalmology. 2007;114:238-245.
10. HEDIS 2006. Glaucoma Screening in Older Adults (GSO). Health Plan Employer Data & Information Set. Vol. 2, Technical Specifications. www.qualitymeasures.ahrq.gov/summary/summary.aspx?ss=1&doc_id=5777. Accessed February 15, 2007.
11. CMS. Preventive Services: Glaucoma Information. www.medicare.gov/health/glaucoma.asp. Accessed February 15, 2007.
12. Fremont A, Lee P, Mangione C, et al. Patterns of care for open-angle glaucoma in managed care. Arch Ophthalmol. 2003;121:777-783.
13. Friedman DS, Nordstrom B, Mozaffari E, Quigley HA. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology. 2005;112:1500-1504.
14. Friedman DS, Nordstrom B, Mozaffari E, Quigley HA. Variations in treatment among adult-onset open-angle glaucoma patients. Ophthalmology. 2005;112:1494-1499.
15. Mansukani SS. Improving adherence to drug-treatment regimens for glaucoma. P&T Digest. 2002;27:49-53.
16. Wilensky J, Fiscella RG, Carlson A, Morris LS, Walt J. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol. 2006;141(1 suppl):S28-S33.
17. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124:1754-1760.
18. Hirsch J. Considerations in the pharmacoeconomics of glaucoma. P&T Digest. 2002;27:32-37.
19. Schmier JK, Halperin MT, Jones ML. The economic implications of glaucoma: a literature review. Pharmacoeconomics. 2007;25:287-308.
20. Noecker RJ, Walt JG. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol. 2006;141(1 suppl):S15-S21.
21. Kymes S. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications [letter]. Am J Ophthalmol. 2006;142:354-355.
22. Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost-effectiveness of bimatoprost compared with other medications. Pharmacoeconomics. 2006;24:251-264.
23. Day DG, Schacknow PN, Sharpe ED, et al. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharm Ther. 2004;20:383-392.
24. Fiscella R, Stewart WC. Letter to the editor: patient persistency with glaucoma therapy. J Ocul Pharm Ther. 2005;21:349-352.
25. Fiscella R, Walt J. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimataprost or latanoprost in patients with glaucoma or ocular hypertension. Drugs Aging. 2006;23:39-47.
26. Gieser DK, Tracy Williams R, O'Connell W, et al. Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US muitisite retrospective study. J Glaucoma. 2006;15:419-425.
27. Chidlow G, Wood JP, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs. 2007;67:725-759.